Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of bevacizumab plus sequential chemotherapy in operable HER2-negative breast cancer
2007-004169-16Phase 2Completed
- Sponsor
- Roche Farma, S.A.
- Start
- Sep 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Roche Farma, S.A. Primary endpoints: Pathological complete response in breast and lymph nodes and Objective clinical response. Started Sep 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-004169-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004169-16.